AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19378685 — intervention group
Group type: COMPARATOR
Intervention: Late loss
Number of subjects: 166
Study 17093162 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 microg/d)
Number of subjects: 200
Study 17093162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 15563963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 66
Study 15563963 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 66
Study 11308044 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 a.m./40 p.m., 80 a.m./40 p.m., or 80 a.m./60 p.m.)
Number of subjects: 55
Study 11308044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11308044 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I
Number of subjects: 55
Study 9133551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (1-g i.v.) during hypoglycemia (HYPO-ACZ)
Number of subjects: 8
Study 9133551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (1-g i.v.) during euglycemia (EUG-ACZ)
Number of subjects: 8
Study 9133551 — intervention group
Group type: COMPARATOR
Intervention: Placebo during hypoglycemia (HYPO-CON)
Number of subjects: 8
Study 8133793 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (Estraderm TTS, Ciba Geigy; 50 micrograms/day; 24 women)
Number of subjects: 81
Study 8133793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin, Wyeth; 0.625 mg/day; 20 subjects)
Number of subjects: 81
Study 8133793 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 subjects)
Number of subjects: 81
Study 3298421 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAM)
Number of subjects: 20
Study 3298421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31983626 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of pharmacists in primary health care teams at 22 sites for approximately 15 months.
Number of subjects: 0
Study 29392574 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of droxidopa in the fed state
Number of subjects: 24
Study 29392574 — intervention group
Group type: COMPARATOR
Intervention: Single 300-mg dose of droxidopa in the fasted state
Number of subjects: 24
Study 29392574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-times-daily (TID) dosing of droxidopa (three 100-mg capsules at 4-h intervals)
Number of subjects: 24
Study 29392574 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine levels after dose 1 of TID dosing
Number of subjects: 24
Study 26986171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (3.7, 4.62, and 5.55 GBq)
Number of subjects: 23
Study 26986171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (3.7 and 4.62 GBq)
Number of subjects: 23
Study 26986171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 23
Study 25425162 — intervention group
Group type: EXPERIMENTAL
Intervention: POCT guided care
Number of subjects: 614
Study 25425162 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 614
Study 24364445 — intervention group
Group type: EXPERIMENTAL
Intervention: Special diet enriched with multicomponent antioxidant foods
Number of subjects: 0
Study 24364445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19637993 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive cardiovascular risk reduction (CaRR) clinic
Number of subjects: 653
Study 19637993 — intervention group
Group type: COMPARATOR
Intervention: Nurse telephone calls
Number of subjects: 653
Study 19637993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653
Study 19637993 — intervention group
Group type: COMPARATOR
Intervention: All groups (CaRR, Nurse Phone, Usual Care)
Number of subjects: 653
Study 17391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 296
Study 17391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher
Number of subjects: 296
Study 17391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical mother
Number of subjects: 296
Study 17391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical father
Number of subjects: 296
Study 17391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical doctor
Number of subjects: 296
Study 15964061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance haemodialysis (HD)
Number of subjects: 61
Study 15964061 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance peritoneal dialysis (CAPD)
Number of subjects: 61
Study 15964061 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 61
Study 12496955 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex plus olanzapine
Number of subjects: 249
Study 12496955 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex plus risperidone
Number of subjects: 249
Study 12496955 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 249
Study 12496955 — intervention group
Group type: COMPARATOR
Intervention: Risperidone monotherapy
Number of subjects: 249
Study 11074888 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy with 5% ethanolamine oleate (median of 5 injections)
Number of subjects: 204
Study 11074888 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 204
Study 8804075 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms desmopressin (DDAVP)
Number of subjects: 24
Study 8804075 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms desmopressin (DDAVP)
Number of subjects: 24
Study 8804075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1346337 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy (1500 mg per day)
Number of subjects: 338
Study 1346337 — intervention group
Group type: COMPARATOR
Intervention: Late therapy (initially placebo, zidovudine started when CD4+ counts fell below 0.2 x 10(9) per liter or AIDS developed)
Number of subjects: 338
Study 1346337 — intervention group
Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 338
Study 1346337 — intervention group
Group type: COMPARATOR
Intervention: Late therapy
Number of subjects: 338
Study 6593675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 gm of tryptophan in divided 0.5-gm doses over a 24-hour period, beginning before the start of treatment
Number of subjects: 50
Study 6593675 — intervention group
Group type: COMPARATOR
Intervention: Placebo on the same dosage schedule
Number of subjects: 50
Study 29762903 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Learning (CAL) training sessions
Number of subjects: 671
Study 29762903 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal Anatomy training sessions in MA Group
Number of subjects: 671
Study 29762903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Anatomy training sessions in CA Group
Number of subjects: 671
Study 27885532 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (0.5 g/kg of ideal body weight)
Number of subjects: 34
Study 27885532 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet without whey protein supplementation (Control)
Number of subjects: 34
Study 27885532 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 34
Study 27885532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 25661800 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' assessment of NRS
Number of subjects: 146
Study 25661800 — intervention group
Group type: COMPARATOR
Intervention: Nutritionists' assessment of NRS
Number of subjects: 146
Study 25422589 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 1.5 hours per day on 5 consecutive days, followed by daily practice at home for 35-40 minutes and group practice for 2 days a week for 18 weeks.
Number of subjects: 260
Study 25422589 — intervention group
Group type: COMPARATOR
Intervention: Control group did not participate in yoga program but received intensive yoga training for 5 days after the study.
Number of subjects: 260
Study 23067910 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced depression care intervention (6-month duration, including problem-solving therapy and/or pharmacotherapy)
Number of subjects: 157
Study 23067910 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 157
Study 19733131 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive liver elastography (Fibroscan)
Number of subjects: 66
Study 17522584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bbeta15-42 (2.4 mg/kg, n = 6)
Number of subjects: 42
Study 17522584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (n = 6)
Number of subjects: 42
Study 17522584 — intervention group
Group type: COMPARATOR
Intervention: Bbeta15-42 in humans (phase I trial, n = 30)
Number of subjects: 42
Study 17522584 — intervention group
Group type: COMPARATOR
Intervention: Random peptide (control; 2.4 mg/kg, n = 6)
Number of subjects: 42
Study 16225722 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40
Study 16225722 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 40
Study 12403039 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 21
Study 10189324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (55% eicosapentaenoic and docosahexaenoic acids) 6 g/d for 3 months and then 3 g/d for 21 months
Number of subjects: 223
Study 10189324 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a fatty acid composition resembling that of the average European diet
Number of subjects: 223
Study 10189324 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate
Number of subjects: 223
Study 8775636 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Number of subjects: 80
Study 8775636 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 80
Study 2302950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus antacids if necessary to maintain gastric pH at greater than or equal to 4
Number of subjects: 40
Study 2302950 — intervention group
Group type: COMPARATOR
Intervention: No drug prophylaxis
Number of subjects: 40
Study 427041 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment (iron dextran, i.v., total dosage infusion of 30-50 ml)
Number of subjects: 16
Study 427041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 16
Study 427041 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment (iron dextran)
Number of subjects: 16
Study 30243957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lipopolysaccharide (LPS, 0.4 ng/kg body weight)
Number of subjects: 43
Study 30243957 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 43
Study 28393342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care program (12 weeks)
Number of subjects: 40
Study 28393342 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative care
Number of subjects: 40
Study 26449884 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA) for 15 minutes
Number of subjects: 16
Study 26449884 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest for 60 minutes)
Number of subjects: 16
Study 23359782 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (cilostazol, clopidogrel, and aspirin)
Number of subjects: 428
Study 23359782 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 428
Study 23359782 — intervention group
Group type: COMPARATOR
Intervention: Both groups (triple and dual)
Number of subjects: 428
Study 21328328 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with capecitabine (1,650 mg/m²/day)
Number of subjects: 240
Study 21328328 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy (CRT) with capecitabine (1,650 mg/m²/day)
Number of subjects: 240
Study 20035644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine warmed to body temperature (36 degrees Celsius)
Number of subjects: 80
Study 20035644 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine at room temperature (18 degrees Celsius)
Number of subjects: 80
Study 17709826 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 23929
Study 17709826 — intervention group
Group type: COMPARATOR
Intervention: Screen-film mammography (SFM)
Number of subjects: 23929
Study 15023706 — intervention group
Group type: EXPERIMENTAL
Intervention: Full disclosure (acceptance of responsibility and an apology)
Number of subjects: 990
Study 15023706 — intervention group
Group type: EXPERIMENTAL
Intervention: Full disclosure
Number of subjects: 990
Study 15023706 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure (expression of regret without acceptance of responsibility or an apology)
Number of subjects: 990
Study 15023706 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure
Number of subjects: 990
Study 11394680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype model
Number of subjects: 0
Study 11394680 — intervention group
Group type: COMPARATOR
Intervention: Exemplar model
Number of subjects: 0
Study 9710394 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study 9710394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study 9710394 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study 9710394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study 9710394 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study 7989940 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil (I‐FU) 1.2 g/m2/d, as a 72‐hour infusion in the first and third weeks of radiation.
Number of subjects: 175
Study 7989940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions).
Number of subjects: 175
Study 7989940 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil (I‐FU)
Number of subjects: 175
Study 2644746 — intervention group
Group type: COMPARATOR
Intervention: 1.0 microgram alphacalcidol (1 alpha‐(OH)‐vitamin D3) over 6 months
Number of subjects: 31
Study 2644746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms alphacalcidol over 1 year
Number of subjects: 31
Study 7967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.05 mg initial dose followed by 0.025 mg repeat injections)
Number of subjects: 29
Study 7967 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.5 mg)
Number of subjects: 29
Study 30170828 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal sizing strategy
Number of subjects: 37
Study 30170828 — intervention group
Group type: COMPARATOR
Intervention: Proximal sizing strategy
Number of subjects: 37
Study 29061161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based risk test with lung cancer risk score
Number of subjects: 67
Study 29061161 — intervention group
Group type: COMPARATOR
Intervention: Control group with no risk score
Number of subjects: 67
Study 29061161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based risk test with 'very high' risk score
Number of subjects: 67
Study 29061161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based risk test with moderate risk score
Number of subjects: 67
Study 29061161 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based risk test with above moderate risk score
Number of subjects: 67
Study 25097030 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium with metamizol
Number of subjects: 54
Study 25097030 — intervention group
Group type: COMPARATOR
Intervention: Metamizol only
Number of subjects: 54
Study 23426111 — intervention group
Group type: EXPERIMENTAL
Intervention: Store and forward teledermatology
Number of subjects: 392
Study 23426111 — intervention group
Group type: COMPARATOR
Intervention: Conventional consultation process
Number of subjects: 392
Study 20931294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (telephone calls and reminder letters)
Number of subjects: 3895
Study 20931294 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3895
Study 19132624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 660
Study 19132624 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 660
Study 16887416 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus 400 mL oral nutritional supplements
Number of subjects: 445
Study 16887416 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet plus placebo
Number of subjects: 445
Study 15006266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol orally
Number of subjects: 120
Study 15006266 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol intravaginally
Number of subjects: 120
Study 15006266 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally
Number of subjects: 120
Study 15006266 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravaginally
Number of subjects: 120
Study 10696831 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 8
Study 9382540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracystic instillation with Epirubicin (arm A)
Number of subjects: 56
Study 9382540 — intervention group
Group type: COMPARATOR
Intervention: Oral administration with 5-FU (arm B)
Number of subjects: 56
Study 9382540 — intervention group
Group type: COMPARATOR
Intervention: Combination of arm A and arm B (arm C)
Number of subjects: 56
Study 1590682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (100 mg/kg/day) plus co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Number of subjects: 64
Study 1590682 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg/day) plus doxycycline (4 mg/kg/day) and co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Number of subjects: 64
Study 1590682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus co-trimoxazole
Number of subjects: 64
Study 1590682 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol plus doxycycline and co-trimoxazole
Number of subjects: 64
Study 1590682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 64
Study 2408417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 63
Study 2408417 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 63
Study 29958044 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriSUS micronutrient fortification (Group A)
Number of subjects: 25
Study 29958044 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 25
Study 29626074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy targeting LDL-C <70 mg/dL
Number of subjects: 5042
Study 29626074 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy targeting LDL-C 100-120 mg/dL
Number of subjects: 5042
Study 27219266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential excision followed by skin autografting 2 days after injury
Number of subjects: 12
Study 27219266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential excision followed by skin autografting 14 days after injury
Number of subjects: 12
Study 27219266 — intervention group
Group type: COMPARATOR
Intervention: No excision (control)
Number of subjects: 12
Study 24435882 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 10
Study 24435882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22788995 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined Social Situation Exercise (ISSE)
Number of subjects: 226
Study 22788995 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic story
Number of subjects: 226
Study 22788995 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured fantasy
Number of subjects: 226
Study 22788995 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 226
Study 20045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at 2/100 Hz
Number of subjects: 36
Study 20045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 36
Study 20045360 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 36
Study 18545187 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC+ (3 sets of 6 repetitions at 40% 1RM concentric and 100% 1RM eccentric)
Number of subjects: 22
Study 18545187 — intervention group
Group type: COMPARATOR
Intervention: TRAD (4 sets of 6 repetitions at 52.5% 1RM)
Number of subjects: 22
Study 11579272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg/day for 2 weeks)
Number of subjects: 75
Study 11579272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (0.2 mg/kg per dose every 12 to 24 hours for three doses)
Number of subjects: 67
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 67
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: RDS infants
Number of subjects: 67
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 67
Study 9553290 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (1 or 2 doses)
Number of subjects: 67